COVID-19 Respiratory Infection
Conditions
Brief summary
The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Pregnant women * Adult female * Admitted to hospital for live birth * Informed consent * Affiliated to the French social security health insurance scheme * Blood donors * Adult male or female * Qualified for whole blood donation (up to 70 years old in France) * Informed consent * Affiliated to the French social security health insurance scheme
Exclusion criteria
* Legal incapacity or limited legal capacity * Subject without health insurance coverage * Exclusion period of another study or exclusion period of the French national healthy volunteer registry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-SARS-CoV-2 spike protein total IgG | at inclusion | Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-SARS-CoV-2 nucleocapsid protein total IgG | at inclusion | Total IgG directed against anti-SARS-CoV-2 nucleocapsid protein as measured by ELISA assay |
Countries
France
Outcome results
None listed